

April 20, 2012

Idaho Medicaid
Pharmacy & Therapeutics Committee
Attn: Tami Eide, PharmD
3232 Elder St.
Boise, ID 83705
Email: eidet@dhw.idaho.gov

Dear Dr. Eide,

Thank you for the opportunity to present new information on Ampyra® (dalfampridine) at the next Idaho Medicaid Pharmacy & Therapeutics Committee meeting on May 11, 2012. If allowed, Acorda would like to make the committee aware of new one-year post-marketing safety data originally presented at ECTRIMS in October of 2011.

The poster we are referencing and enclosing is: Jara M, et al. Dalfampridine Extended Release Tablets: One Year of Post-Marketing Safety Experience in the United States. Poster presented at the 5th Joint Triennial Congress of the European (ECTRIMS) and Americas (ACTRIMS) Committees for Treatment and Research in Multiple Sclerosis; October 19-22, 2011; Amsterdam, The Netherlands.

Some of the main points we would like to highlight are:

- Column 2, first bullet under Results: The exposure of dalfampridine to 46,200 patients (14,500 patient years) during the first year.
- Column 3, second bullet under Common Adverse Adverts: During the first year of marketing, the majority of the most frequently reported adverse events were previously detailed in the product labeling.
- Column 3, last bullet under Table 1: New findings of clinical significance reported from the post-marketing data are related to inappropriate dosing and lack of efficacy.
- Column 4, first and third bullets under Seizure and Column 5, first and second bullets, before and after Figure 2: An update on seizures, incidence, timing, prevalence in the MS population in general, and confounding factors that impact seizure incidence.

Thank you for taking the time to consider our request.

Sincerely,
Acorda Therapeutics